MarketingRx roundup: Aduhelm can’t get traction with docs; Pfizer presses vaccine effort during NFL playoffs
While much of the pharma industry’s attention pivoted to CMS’ preliminary decision last week to only cover Biogen’s controversial Alzheimer’s drug Aduhelm in clinical trials and its effect on prescribing, neurologists were already hesitant.
Spherix Global Insights has been tracking neurologists’ perception of Aduhelm. Its latest six-month survey, taken before the CMS decision, found that while now most neurologists have had interactions with Aduhelm sales reps, the majority of neurologists are still not actively recommending the drug.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.